Empowering patients, advocates, and organisations with a shared view of the cell and gene therapy (CGT) ecosystem isn’t just a nice-to-have, it’s a strategic imperative. By aligning these stakeholders around a common understanding of how therapies are developed, regulated, manufactured, and accessed, we unlock a virtuous cycle: greater transparency builds trust, which attracts investment and innovation, which in turn makes treatments more scalable and affordable.

In practical terms, when patient groups are equipped with meaningful insights on manufacturing constraints, regulatory pathways, and reimbursement challenges, they can engage more effectively in policy debates, collaborations, and advocacy. Similarly, organisations and industry players benefit from understanding patient priorities and system bottlenecks early in the development journey. The outcome? Faster, fairer access to advanced therapies for the people who need them most.

In the rapidly evolving CGT world, where complexity is high and timelines tight, information truly becomes power, and shared power, when deployed across the ecosystem, has the potential to democratise access and accelerate impact.

Link to article